Triple-Neg Breast Cancer

Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer.
Peterlongo P, Figlioli G, Deans AJ, Couch FJ.
NPJ Breast Cancer. 2021 Sep 28;7(1):130. doi: 10.1038/s41523-021-00338-1.

Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer.
Clark CA, Yang ES.
Front Oncol. 2021 Sep 24;10:703802. doi: 10.3389/fonc.2021.703802.

Genetic testing in patients with triple-negative or hereditary breast cancer.
Bernstein-Molho R, Evron E, Yerushalmi R, Paluch-Shimon S.
Curr Opin Oncol. 2021 Sep 1. doi: 10.1097/CCO.0000000000000784. Epub ahead of print.

Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study.
Koh SJ, Ohsumi S, Takahashi M, Fukuma E, Jung KH, Ishida T, Dai MS, Chang CH, Dalvi T, Walker G, Bennett J, O'Shaughnessy J, Balmaña J.
Breast Cancer. 2021 Aug 31. doi: 10.1007/s12282-021-01283-4. Epub ahead of print.

Understanding the Clinical Implications of Low Penetrant Genes and Breast Cancer Risk.
Vaidyanathan A, Kaklamani V.
Curr Treat Options Oncol. 2021 Aug 23;22(10):85. doi: 10.1007/s11864-021-00887-4.

Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach.
Kedzierawski P, Macek P, Ciepiela I, Kowalik A, Gozdz S.
Diagnostics (Basel). 2021 Jun 23;11(7):E1144. doi: 10.3390/diagnostics11071144.

Letter to the editor regarding: 'Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis'.
Wang Y, van den Broek AJ, Schmidt MK.
Breast Cancer Res Treat.2021 Jun 16. doi: 10.1007/s10549-021-06289-2. Epub ahead of print.

Review:

Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis.

Clinical, radiometabolic and immunologic effects of olaparib in locally advanced triple negative breast cancer: the OLTRE window of opportunity trial.
Schettini F, Corona SP, Giudici F, Strina C, SIRICO M, Bernocchi O, Milani M, Ziglioli N, Aguggini S, Azzini C, Barbieri G, Cervoni V, Cappelletti MR, Molteni A, Lazzari MC, Ferrero G, Ungari M, Marasco E, Bruson A, Xumerle L, Zago E, Cerra D, Loddo M, Williams GH, Paris I, Scambia G, Generali D.
Front Oncol. 2021 Jun 11;10:686776. doi: 10.3389/fonc.2021.686776.

Study of the Genetic Variants in BRCA1/2 and Non-BRCA Genes in a Population-Based Cohort of 2155 Breast/Ovary Cancer Patients, Including 443 Triple-Negative Breast Cancer Patients, in Argentina.
Solano AR, Mele PG, Jalil FS, Liria NC, Podesta EJ, Gutiérrez LG.
Cancers (Basel). 2021 May 31;13(11):2711. doi: 10.3390/cancers13112711.

LitAlert ~~ GeneLit.com

Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer.
Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, Perez EA, Anderson BO, Penault-Llorca F, Conte P, El Saghir NS, Yip CH, Ghosn M, Poortmans P, Shehata MA, Giuliano AE, Leung JWT, Guarneri V, Gligorov J, Gulluoglu BM, Aziz HA, Frolova M, Sabry M, Balch CM, Orecchia R, El-Zawahry HM, Al-Sukhun S, Karim KA, Kandil A, Paltuev RM, Foheidi M, El-Shinawi M, ElMahdy M, Abulkhair O, Yang W, Aref AT, Bakkach J, Eldin NB, Elghazawy H.
Cancers (Basel). 2021 May 8;13(9):2262. doi: 10.3390/cancers13092262.